Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

79.45 +2.44 (+3.17%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

1 Surging Stock for Long-Term Investors and 2 We Brush Off

July 01, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗

June 25, 2026

Via Chartmill

2 Profitable Stocks Worth Your Attention and 1 We Question

June 18, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Topics Credit Cards

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

June 03, 2026

What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst re...

Via StockStory

Topics Economy

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗

June 03, 2026

Via Chartmill

Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback ↗

May 11, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

March 06, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗

February 17, 2026

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation ↗

February 17, 2026

Via Chartmill

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 18, 2026

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the exp...

Via StockStory

Topics Earnings

Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

May 13, 2026

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...

Via StockStory

Topics Economy

Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)

May 12, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

Via StockStory

Topics Artificial Intelligence

HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

May 12, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ...

Via StockStory

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup ↗

January 29, 2026

Via Chartmill

Halozyme (HALO) Q1 2026 Earnings Transcript ↗

May 11, 2026

Halozyme (HALO) Q1 2026 Earnings Transcript

Via The Motley Fool

Halozyme Therapeutics Q1 Earnings Call Highlights ↗

May 11, 2026

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced...

Via MarketBeat

Topics Earnings

Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates

May 11, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ...

Via StockStory

Halozyme Therapeutics Earnings: What To Look For From HALO

May 09, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what t...

Via StockStory

Topics Artificial Intelligence

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm

April 21, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

3 Cash-Producing Stocks with Exciting Potential

April 10, 2026

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain ...

Via StockStory

2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore

April 09, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Via StockStory

1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

April 08, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Via StockStory

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

March 24, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz...

Via StockStory

Topics Artificial Intelligence

2 Reasons to Like HALO (and 1 Not So Much)

February 24, 2026

Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that...

Via StockStory

Topics Stocks

Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

Halozyme (HALO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

February 17, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 51.6% year on year to $451.8 million. The...

Via StockStory

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

3 Small-Cap Stocks with Solid Fundamentals

February 08, 2026

In today’s market, large companies dominate the landscape and grow their leads by acquiring smaller competitors - a trend that will accelerate with the Trump administration. However, some lesser-known...

Via StockStory

Topics Government

3 Growth Stocks Set to Flourish

February 01, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack

January 29, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.